Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers November 18, 2017
Pharmacy Choice - Pharmaceutical News - Photocure ASA : UPDATE ON MEDICARE REIMBURSEMENT FOR BLUE LIGHT CYSTOSCOPY WITH CYSVIEW - November 18, 2017

Pharmacy News Article


Oslo, Norway, July 17, 2017: Photocure ASA (OSE: PHO), announced today that the United States Centers for Medicare & Medicaid Services (CMS) has released the Proposed Rule outlining its 2018 plan to reimburse hospital outpatient departments using Blue Light Cystoscopy (BLCTM) with Cysview. To ensure appropriate reimbursement for BLCTM with Cysview, CMS has proposed to create a new set of codes specific to Blue Light Cystoscopy allowing for improved reimbursement for those procedures.

The CMS draft rule for Medicare patients can be accessed at:

"We are grateful that CMS has heard the concerns from stakeholders that the current Medicare reimbursement for Blue Light Cystoscopy procedures involving Cysview is creating a barrier to patient access to reasonable and necessary care," stated Kjetil Hestdal, President and CEO of Photocure ASA. "We are pleased that CMS has proposed to improve the reimbursement to hospitals for Blue Light Cystoscopy, and we will submit comments in support of the proposal in the coming weeks," he noted.

The effectiveness and benefits of Blue Light Cystoscopy (BLCTM) with Cysview for improved detection and management of bladder cancer have been recognized by leading urology associations including the AUA (American Urological Association), and SUO (Society of Urological Oncology) and patient groups have recognized the potential of using Cysview as well. In 2016, BLCTM with Cysview was adopted into the AUA/SUO Non-Muscle Invasive Bladder Cancer (NMIBC) guidelines.

The comment period for the Proposed Rule closes in early September, and CMS is expected to issue a Final Rule in the fourth quarter of 2017 effective on January 1, 2018.

About Bladder Cancer
Bladder cancer is the fifth most commonly diagnosed cancer 
in the US and is the fourth most common cancer found in men 
in the US.[1],[2],[3] In 2016, it is estimated that 76,960 
cases of bladder cancer will occur along with 16,390 deaths 
due to bladder cancer. 

Bladder cancer is one of the most expensive cancers to manage, accounting for approximately $3.7 billion in direct costs each year.[4],[5]

Bladder cancer is classified into two types, non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of invasion in the bladder wall[2].NMIBC remains in the inner layer of cells lining the bladder. These cancers are the most common (70%) of all BC cases and include the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. MIBC is when the cancer has grown into deeper layers of the bladder wall. These cancers, including subtypes T2, T3 and T4, are more likely to spread and are harder to treat[2].

About Hexvix/Cysview 
Hexvix/Cysview is a drug that is selectively taken up by 
cancer cells in the bladder making them glow bright pink 
during Blue Light Cystoscopy (BLCTM). BLCTM with 
Hexvix /Cysview improves the detection of tumors and leads 
to more complete resection, less residual tumors and better 
management decisions.

Cysview is the tradename in the US and Canada, Hexvix is 
the tradename in all other markets. Photocure is 
commercializing Hexvix/Cysview directly in the US and the 
Nordic region, and has strategic partnerships for the 
commercialization of Hexvix/Cysview in Europe, Canada, 
Australia and New Zealand. Please refer to
partners for further information on our commercial partners.

About Photocure Photocure, headquartered in Oslo Norway, is a specialty pharmaceutical company focusing on urology. Based on its unique proprietary Photocure Technology platform, Photocure is committed to developing and commercializing highly selective and minimally invasive solutions to improve health outcomes for patients worldwide. The company is listed on the Oslo Stock Exchange (OSE: PHO). More information about Photocure is available at, and

For more information, please contact:
Kjetil Hestdal
President and CEO, Photocure ASA
Tel: +47 913 19 535

Erik Dahl
Chief Financial Officer
Tel: +47 450 55 000

[1] SEER Cancer Statistics Factsheets: Bladder Cancer. 
National Cancer Institute. Bethesda, MD. Accessed 
April 2016.
[2] Bladder Cancer. American Cancer Society.
085-pdf.pdf. Accessed April 2016.
[3] Hall M, Chang S, Dalbagni G et al. Guideline for the 
Management of Nonmuscle Invasive Bladder Cancer (Stages Ta, 
T1, and Tis): 2007 Update. J Urol. 2007;178 (6):2314-2330.
[4] Avritscher EB et al., Clinical model of lifetime cost of 
treating bladder cancer and associated complications. 
Urology. 2006; 68:549-553.
[5] Botteman et al. Clinical model of lifetime costs of 
treating bladder cancer: a comprehensive review of the 
published literature. Pharmacoeconomics. 2003; 21:315-1330. 
[6] Bladder Cancer. American Cancer Society.
085-pdf.pdf. Accessed April 2016.
[7] Bladder Cancer. American Cancer Society.
085-pdf.pdf. Accessed April 2016.

Click here for more information:

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Nov 19: Biosimilar Drugs: Legal, Regulatory & Safety Considerations
Nov 20: Obesity Management: Overview of Pharmacotherapy
Nov 21: Standards of Practice for Filling Controlled Substance Prescriptions in Florida
Nov 22: Medical Marijuana: Examining the Science, Not the Politics
Nov 27: Drug Diversion and the Law: Updates and Considerations
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement